March 1, 2023
Genome editing summits are generally friendly, nerdy affairs, but for a moment at a Lisbon hotel last June, the conversation at the FASEB genome engineering conference grew tense.
Tessera Therapeutics chief scientist Michael Holmes had just finished presenting a much-anticipated peek at a technology the company had previously said could “revolutionize genetic medicine” and “cure nearly any genetic disease.” It was a rare moment: Tessera had raised around $600 million and passed a $1 billion valuation, but had never published in academic medical journals.
To Nicole Gaudelli, sitting in the audience, parts of the glimpse Holmes offered looked suspiciously familiar. It resembled a technology her former adviser, Harvard and Broad Institute biochemist David Liu, published in 2019 called prime editing. That paper captured headlines around the world because it promised a more precise way to fix genomes. Prime editing was quickly picked up by hundreds of outside labs, and spawned another billion-dollar company called Prime Medicine.
She stood up and raised her hand. “How is that differentiated from Prime Medicine?” she said, according to three people present.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Authors
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect